CD147 mediates transforming growth factor‑β1‑induced epithelial‑mesenchymal transition and cell invasion in squamous cell carcinoma of the tongue

Suzuki,Shinsuke; Toyoma,Satoshi; Tsuji,Tadahiro; Kawasaki,Yohei; Yamada,Takechiyo

doi:10.3892/etm.2019.7230

CD147 mediates transforming growth factor‑β1‑induced epithelial‑mesenchymal transition and cell invasion in squamous cell carcinoma of the tongue

Authors:
- Shinsuke Suzuki
- Satoshi Toyoma
- Tadahiro Tsuji
- Yohei Kawasaki
- Takechiyo Yamada
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, Akita University Graduate School of Medicine, Akita 010‑8543, Japan
Published online on: January 31, 2019 https://doi.org/10.3892/etm.2019.7230
Pages: 2855-2860

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial‑mesenchymal transition (EMT) is a physiological process in which epithelial cells attain the motile and invasive characteristics of mesenchymal cells, which results in the development of increased migratory and invasive cell behavior, serving as a vital mechanism of cancer progression. Hence, controlling the EMT for cancer treatment, including head and neck squamous cell carcinoma (HNSCC), is imperative. Among EMT‑associated factors, transforming growth factor‑β (TGF‑β) is a well‑established potent inducer. Recent research has revealed that CD147, a member of the immunoglobulin superfamily, promotes the EMT. However, the role of CD147 in the EMT and the following tumorigenicity in HNSCC has not been completely elucidated. This study aims to investigate the role of CD147 in the EMT and related tumorigenicity in HNSCC. The present study used two HNSCC cell lines, SAS and FaDu, for in vitro studies. In HNSCC cells, TGF‑β1 induced spindle‑shaped morphological changes, and western blot analysis revealed that TGF‑β1 induced changes in EMT markers, downregulation of vimentin, and upregulation of E‑cadherin, yet increased CD147. In addition, TGF‑β1 increased cell migration in HNSCC cells. However, a TGF‑β1‑induced alteration in EMT makers was attenuated with CD147 silencing by small interfering RNA (siRNA) in SAS cells. In addition, the TGF‑β1‑induced cell invasion of SAS was attenuated with CD147 silencing. In conclusion, the present study suggests that CD147 mediates TGF‑β1‑induced EMT and tumorigenicity in HNSCC. Hence, CD147 may serve as a vital therapeutic target in HNSCC.

View Figures

View References

1	Cho J, Johnson DE and Grandis JR: Therapeutic implications of the genetic landscape of head and neck cancer. Semin Radiat Oncol. 28:2–11. 2018. View Article : Google Scholar : PubMed/NCBI
2	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
3	Wendt MK, Allington TM and Schiemann WP: Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Futur Oncol. 5:1145–1168. 2009. View Article : Google Scholar
4	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
5	Miettinen PJ, Ebner R, Lopez AR and Derynck R: TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. J Cell Biol. 127:2021–2036. 1994. View Article : Google Scholar : PubMed/NCBI
6	Smith A, Teknos TN and Pan Q: Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 49:287–292. 2013. View Article : Google Scholar : PubMed/NCBI
7	Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S and Birembaut P: Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem. 47:1575–1580. 1999. View Article : Google Scholar : PubMed/NCBI
8	Suzuki S, Sato M, Senoo H and Ishikawa K: Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblast: Involvement of EMMPRIN and MT1-MMP. Exp Cell Res. 293:259–266. 2004. View Article : Google Scholar : PubMed/NCBI
9	Xu T, Zhou M, Peng L, Kong S, Miao R, Shi Y, Sheng H and Li L: Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in c. Int J Clin Exp Pathol. 7:7432–7441. 2014.PubMed/NCBI
10	Hibino T, Sakaguchi M, Miyamoto S, Yamamoto M, Motoyama A, Hosoi J, Shimokata T, Ito T, Tsuboi R and Huh NH: S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res. 73:172–183. 2013. View Article : Google Scholar : PubMed/NCBI
11	Takahashi M, Suzuki S and Ishikawa K: Cyclophilin A-EMMPRIN interaction induces invasion of head and neck squamous cell carcinoma. Oncol Rep. 27:198–203. 2012.PubMed/NCBI
12	Suzuki S, Honda K, Nanjo H, Iikawa N, Tsuji T, Kawasaki Y, Yamazaki K, Sato T, Saito H, Shiina K and Ishikawa K: CD147 expression correlates with lymph node metastasis in T1-T2 squamous cell carcinoma of the tongue. Oncol Lett. 14:4670–4676. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ru NY, Wu J, Chen ZN and Bian H: HAb18G/CD147 is involved in TGF-β-induced epithelial-mesenchymal transition and hepatocellular carcinoma invasion. Cell Biol Int. 39:44–51. 2015. View Article : Google Scholar : PubMed/NCBI
14	Liu F, Gu LN, Shan BE, Geng CZ and Sang MX: Biomarkers for EMT and MET in breast cancer: An update. Oncol Lett. 12:4869–4876. 2016. View Article : Google Scholar : PubMed/NCBI
15	Katsuno Y, Lamouille S and Derynck R: TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zhu C, Pan Y, He B, Wang B, Xu Y, Qu L, Bao Q, Tian F and Wang S: Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells. Oncol Rep. 25:425–432. 2011.PubMed/NCBI
17	Ma C, Wang J, Fan L and Guo Y: Inhibition of CD147 expression promotes chemosensitivity in HNSCC cells by deactivating MAPK/ERK signaling pathway. Exp Mol Pathol. 102:59–64. 2017. View Article : Google Scholar : PubMed/NCBI
18	Suzuki S and Ishikawa K: Combined inhibition of EMMPRIN and epidermal growth factor receptor prevents the growth and migration of head and neck squamous cell carcinoma cells. Int J Oncol. 44:912–917. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, et al: Nivolumab vs. investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 81:45–51. 2018. View Article : Google Scholar : PubMed/NCBI
20	Kelderman S, Schumacher TN and Haanen JB: Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol. 8:1132–1139. 2014. View Article : Google Scholar : PubMed/NCBI
21	Bu X, Mahoney KM and Freeman GJ: Learning from PD-1 resistance: New combination strategies. Trends Mol Med. 22:448–451. 2016. View Article : Google Scholar : PubMed/NCBI
22	Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP and Chouaib S: New insights into the role of EMT in tumor immune escape. Mol Oncol. 11:824–846. 2017. View Article : Google Scholar : PubMed/NCBI